Huvepharma working to tight deadline after rating delay
Bulgarian pharmaceutical company Huvepharma faces a race to meet Friday’s deadline for commitments on its €275m acquisition loan after rating agencies delayed announcing the deal’s credit rating.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts